Cutaneous field cancerization: clinical, histopathological and therapeutic aspects
Open Access
- 1 October 2013
- journal article
- review article
- Published by FapUNIFESP (SciELO) in Anais Brasileiros de Dermatologia
- Vol. 88 (5), 775-786
- https://doi.org/10.1590/abd1806-4841.20132300
Abstract
The concept of "field cancerization" was first introduced by Slaughter in 1953 when studying the presence of histologically abnormal tissue surrounding oral squamous cell carcinoma. It was proposed to explain the development of multiple primary tumors and locally recurrent cancer. Organ systems in which field cancerization has been described since then are: head and neck (oral cavity, oropharynx, and larynx), lung, vulva, esophagus, cervix, breast, skin, colon, and bladder. Recent molecular studies support the carcinogenesis model in which the development of a field with genetically altered cells plays a central role. An important clinical implication is that fields often remain after the surgery for the primary tumor and may lead to new cancers, designated presently as "a second primary tumor" or "local recurrence," depending on the exact site and time interval. In conclusion, the development of an expanding pre-neoplastic field appears to be a critical step in epithelial carcinogenesis with important clinical consequences. Diagnosis and treatment of epithelial cancers should not only be focused on the tumor but also on the field from which it developed. The most important etiopathogenetic, clinical, histopathological and therapeutic aspects of field cancerization are reviewed in this article.Keywords
This publication has 51 references indexed in Scilit:
- Ingenol Mebutate Field-Directed Treatment of UVB-Damaged Skin Reduces Lesion Formation and Removes Mutant p53 PatchesJournal of Investigative Dermatology, 2012
- Ingenol Mebutate Gel for Actinic KeratosisNew England Journal of Medicine, 2012
- Aesthetic effects of topical photodynamic therapyJournal of the European Academy of Dermatology and Venereology, 2010
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical UseCold Spring Harbor Perspectives in Biology, 2009
- Photodynamic Therapy With Methyl Aminolevulinate for Prevention of New Skin Lesions in Transplant Recipients: A Randomized StudyTransplantation, 2008
- Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patientsBritish Journal of Dermatology, 2007
- Tenascin-C patterns and splice variants in actinic keratosis and cutaneous squamous cell carcinomaBritish Journal of Dermatology, 2006
- Imiquimod 5% cream for the treatment of actinic keratosis: Results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histologyJournal of the American Academy of Dermatology, 2004
- Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trialsJournal of the American Academy of Dermatology, 2004
- Does intermittent “pulse” topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation?Journal of the American Academy of Dermatology, 1998